Novaremed

Novaremed, a privately held clinical-stage biopharmaceutical company, is developing effective and safe treatment options for managing chronic pain as an alternative to opioids. The company's lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, FDA Fast Track Designation, and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy. The earlier stage pipeline addressing chronic pain includes candidates MP-101 (Phase 2 stage), targeting prevention and treatment of chemotherapy-induced peripheral neuropathy; and MP-103 (preclinical stage). Novaremed's clinical development portfolio aims to satisfy high medical patient needs and societal demands by alleviating the burden of pain associated with diabetes and cancer for patients and countering over-reliance on addictive treatments. Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland).

Novaremed has raised $67.16M in total funding across 6 rounds. The company is currently at the A stage. Key investors include GEM Global Yield LLC, Shareholders, Undisclosed Investor(s).

Novaremed was founded in 2008 by Eliahu Kaplan, M.D. (Founder & CEO).

Novaremed operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

Novaremed is based in HaSivim Street 24, Petah Tikva, Israel, Center District. The company also has offices abroad.